OBJECTIVE: Although adjuvant trastuzumab improves survival in patients with HER2-positive early breast cancer, there is growing concern about the long-term effect of trastuzumab-induced cardiotoxicity (TIC). We retrospectively assessed the incidence of TIC and heart failure (HF) to identify possible risk and protective factors. DESIGN: Retrospective study. SETTING: Institute for Cancer Research and Treatment, Medical Oncology Department. PATIENTS: Consecutive patients who started adjuvant trastuzumab between 2007 and 2010. MAIN OUTCOME: Measures TIC was defined as an absolute left ventricular ejection fraction (LVEF) decrease ≥ 15 points from baseline or a LVEF<50%. Logistic regression was used to estimate OR and their 95% CI in order to evaluate the risk of TIC, considering potential cardiac risk factors (hypertension, hypercholesterolaemia, diabetes mellitus, smoke, cardiac ischaemia and previous chest radiotherapy) and protective factors (β-blockers, ACE inhibitors and/or angiotensin receptor blockers). RESULTS: Among 179 patients, 78 cases of TIC (44%, 95% CI 37% to 51%) and four cases of HF (2%, 95% CI 0% to 4%) were reported. 14 patients stopped trastuzumab as a result of TIC. None of the cardiac risk factors or concomitant cardiovascular medications altered the risk of TIC. A previous cumulative dose >240 mg/m(2) of doxorubicin or >500 mg/m(2) of epirubicin increased the risk of TIC compared with lower doses (OR 3.07; 95% CI 1.29 to 7.27, p=0.0011). CONCLUSIONS: TIC is a frequent, albeit generally mild, adverse event in clinical practice. Further studies are warranted to better define the risk of and protective factors for TIC.
OBJECTIVE: Although adjuvant trastuzumab improves survival in patients with HER2-positive early breast cancer, there is growing concern about the long-term effect of trastuzumab-induced cardiotoxicity (TIC). We retrospectively assessed the incidence of TIC and heart failure (HF) to identify possible risk and protective factors. DESIGN: Retrospective study. SETTING: Institute for Cancer Research and Treatment, Medical Oncology Department. PATIENTS: Consecutive patients who started adjuvant trastuzumab between 2007 and 2010. MAIN OUTCOME: Measures TIC was defined as an absolute left ventricular ejection fraction (LVEF) decrease ≥ 15 points from baseline or a LVEF<50%. Logistic regression was used to estimate OR and their 95% CI in order to evaluate the risk of TIC, considering potential cardiac risk factors (hypertension, hypercholesterolaemia, diabetes mellitus, smoke, cardiac ischaemia and previous chest radiotherapy) and protective factors (β-blockers, ACE inhibitors and/or angiotensin receptor blockers). RESULTS: Among 179 patients, 78 cases of TIC (44%, 95% CI 37% to 51%) and four cases of HF (2%, 95% CI 0% to 4%) were reported. 14 patients stopped trastuzumab as a result of TIC. None of the cardiac risk factors or concomitant cardiovascular medications altered the risk of TIC. A previous cumulative dose >240 mg/m(2) of doxorubicin or >500 mg/m(2) of epirubicin increased the risk of TIC compared with lower doses (OR 3.07; 95% CI 1.29 to 7.27, p=0.0011). CONCLUSIONS: TIC is a frequent, albeit generally mild, adverse event in clinical practice. Further studies are warranted to better define the risk of and protective factors for TIC.
Authors: Stefania Mantarro; Marta Rossi; Martina Bonifazi; Roberto D'Amico; Corrado Blandizzi; Carlo La Vecchia; Eva Negri; Lorenzo Moja Journal: Intern Emerg Med Date: 2015-12-28 Impact factor: 3.397
Authors: Mi Hyung Lee; Jeong Yee; Young Ju Kim; Jin Young Moon; Joo Hee Kim; Sandy Jeong Rhie; Hye Sun Gwak Journal: Med Oncol Date: 2017-11-21 Impact factor: 3.064
Authors: Naomi Dempsey; Amanda Rosenthal; Nitika Dabas; Yana Kropotova; Marc Lippman; Nanette H Bishopric Journal: Breast Cancer Res Treat Date: 2021-06-11 Impact factor: 4.872